autoimmune attack

2 Immune Cells Likely Culprits of NMOSD Attacks, Study Suggests

The activation of two types of immune cells — called natural killer (NK) and natural killer T-cells (NKT) — may contribute to the abnormal immune attacks that drive neuromyelitis optica spectrum disorder (NMOSD), a study suggested. The profile of these cells in NMOSD patients differed notably from that observed…

Uplizna Reduces NMOSD Attack Severity, Analysis Shows

Uplizna (inebilizumab-cdon) effectively reduced the severity of attacks in people with neuromyelitis optica spectrum disorder (NMOSD) who continued to experience attacks after being treated with the therapy during the N-MOmentum Phase 2/3 clinical trial, recent data analysis shows. The data also demonstrated lower levels of key disease-related biomarkers,…

Analysis: Uplizna Provides Long-term NMOSD Attack Prevention

Uplizna (inebilizumab-cdon) safely prevented autoimmune attacks in 83% of people with neuromyelitis optica spectrum disorder (NMOSD) who received the treatment for four or more years, data from the N-MOmentum Phase 2/3 clinical trial show. Among those who experienced relapses, most did so during the first year of treatment.